Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,676,508
  • Shares Outstanding, K 27,688
  • Annual Sales, $ 91,280 K
  • Annual Income, $ -145,230 K
  • EBIT $ -29 M
  • EBITDA $ -37 M
  • 60-Month Beta 0.32
  • Price/Sales 6.24
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 73.23% (-13.19%)
  • Historical Volatility 64.08%
  • IV Percentile 25%
  • IV Rank 13.48%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 14) 5.70 (9.94%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 125
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 723
  • Open Int (30-Day) 2,815
  • Expected Range 51.59 to 62.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.10
  • Number of Estimates 6
  • High Estimate -0.64
  • Low Estimate -1.78
  • Prior Year -1.28
  • Growth Rate Est. (year over year) +14.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.85 +22.26%
on 02/11/26
63.47 -9.75%
on 03/05/26
+9.38 (+19.58%)
since 02/05/26
3-Month
42.00 +36.38%
on 01/06/26
63.47 -9.75%
on 03/05/26
+12.93 (+29.15%)
since 12/05/25
52-Week
15.32 +273.89%
on 03/19/25
63.47 -9.75%
on 03/05/26
+40.53 (+241.97%)
since 03/05/25

Most Recent Stories

More News
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease...

ANAB : 57.28 (-5.40%)
Anaptys Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 57.28 (-5.40%)
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage...

ANAB : 57.28 (-5.40%)
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 57.28 (-5.40%)
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 57.28 (-5.40%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 57.28 (-5.40%)
VNDA : 7.91 (-3.54%)
Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 57.28 (-5.40%)
Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

ANAB : 57.28 (-5.40%)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...

ANAB : 57.28 (-5.40%)
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...

ANAB : 57.28 (-5.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 69.96
2nd Resistance Point 66.71
1st Resistance Point 62.00
Last Price 57.28
1st Support Level 54.04
2nd Support Level 50.79
3rd Support Level 46.08

See More

52-Week High 63.47
Last Price 57.28
Fibonacci 61.8% 45.08
Fibonacci 50% 39.40
Fibonacci 38.2% 33.71
52-Week Low 15.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar